Stock Price Prediction

RAPP stock has a bullish outlook with analysts projecting significant upside. Jones Trading gives it a Buy rating with a price target of $35.70, representing a 37.84% increase from its current price of $25.90, driven by strong institutional backing and growth potential in CNS precision medicines. Another analyst sets an even higher target of $42, citing optimism around its lead program RAP-219 and strategic resource allocation.

RAPP stock currently trades at $25.90, with analysts projecting a 37.84% upside to $35.70, supported by strong institutional ownership and a promising pipeline in CNS disorders. However, its negative EPS (-2.61) and regulatory delays in trials pose risks. The stock's near-term trajectory depends on resolving these challenges and delivering clinical milestones.